Hypoxia promotes the invasion and metastasis of laryngeal cancer cells via EMT

Zuo, Jianhong; Wen, Juan; Lei, Mingsheng; Wen, Ming‐Shien; Li, Sai; Lv, Xiu; Liu, Zhaoyang; Ge, Wen

doi:10.1007/s12032-015-0716-6

Cited by 57 publications

(49 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All of the included studies measured the expression of GLUT1 by means of immunohistochemistry (IHC) staining or PCR in human tissues, and the cut-off values varied across studies. Among the studies, 4 evaluated lung cancer [5–8], 3 evaluated pancreatic cancer [9–11], 3 evaluated breast cancer [12, 14], 2 evaluated gallbladder cancer [10, 15], 2 evaluated gastric cancer [16, 17], 2 evaluated colorectal cancer [18, 19], 2 evaluated laryngeal cancer [20, 21], and 1 each evaluated hypopharyngeal cancer [22], endometrial cancer [23], salivary gland tumor [24], adrenocortical cancer [25], liver cancer [26], ampulla of Vater cancer [10], extrahepatic bile duct cancer [10], oral cancer [27], neuroblastic tumors [28], cervical cancer [29], ovarian cancer [30] and esophageal cancer [31]. Due to the retrospective design of the included studies, only five studies examined both OS and DFS [6, 12, 14, 25, 29].…”

Section: Resultsmentioning

confidence: 99%

“…Due to the retrospective design of the included studies, only five studies examined both OS and DFS [6, 12, 14, 25, 29]. Sixteen studies investigated the association between GLUT1 level and OS [7–11, 15–21, 24, 27, 28, 30], while four studies investigated the association between GLUT1 and DFS [5, 13, 23, 26]. Studies by Mineta [22] reported relapse-free survival data, whereas study by Sawayama [31] reported data of relapse-free survival and cancer-specific survival.…”

Section: Resultsmentioning

confidence: 99%

“…Some studies indicated that there was a poor prognostic value of GLUT1 in oral squamous cell carcinoma [27], malignant salivary gland tumors [24], colorectal cancer [18, 19], gastric cancer [16, 17], gallbladder cancer [10, 15], extrahepatic bile duct cancer [10], adrenocortical carcinoma [25] and neuroblastic tumor [28]. Others studies found there was no significant association between GLUT1 expression with prognosis in laryngeal cancer [20, 21], ampulla of vater cancer [10], extrahepatic bile duct cancer [10], cervical cancer [29], and ovarian cancer [2]. As for breast cancer, Kang [14] found there was no significant association between GLUT1 expression with OS, while Jang [12] identified a poor prognostic value of GLUT1 in their studies.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

Increased glycolysis is one of the hallmarks of cancer. The abnormal expression of glucose transporter 1 (GLUT1) was reported to be associated with resistance to current therapy and poor prognosis. Numerous studies have investigated the correlation between GLUT1 expression and prognosis in cancers, but the conclusions are still controversial. Here, we conducted a meta-analysis to explore the association between GLUT1 and survival in human cancers. PubMed, Springer, Medline, and Cochrane Library were searched carefully to identify eligible studies evaluating prognostic value of GLUT1 in cancers. Twenty-seven studies with 4079 patients were included in the present study. Our pooled results identified that increased expression of GLUT1 was associated with unfavorable overall survival (HR = 1.780, 95% CI = 1.574–.013, p < 0.001)) and poorer disease-free survival (HR = 1.95, 95% CI = 1.229–3.095, p = 0.003). Furthermore, overexpression of GLUT1 linked with poor differentiated tumors (RR = 1.380, 95% CI = 1.086–1.755, p = 0.009; I2 = 72.0%, p < 0.001), positive lymph node metastasis (RR = 1.395, 95% CI = 1.082–1.799, p = 0.010; I2 = 70.8%, p = 0.002) and larger tumor size (RR = 1.405, 95% CI = 1.231–1.603, p < 0.001; I2 = 37.3%, p = 0.093). This systematic review and meta-analysis indicated that the GLUT1 may serve as an ideal prognostic biomarker in various cancers.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…During the development of EMT, the expressions of epithelial markers such as E-cadherin, zonula occludens-1, and claudins decrease while the expressions of mesenchymal markers such as vimentin, N-cadherin, and fibronectin increase [5]. The EMT process in HCC cells can be regulated by various factors, including hypoxia [6], cytokines [7], long non-coding RNAs (lncRNAs) [8], microRNAs [9], and so on, and targeting the EMT process has been found to be an attractive and promising strategy to prevent the metastasis of HCC [7]. …”

Section: Introductionmentioning

confidence: 99%

Long non-coding RNA TUSC7 acts a molecular sponge for miR-10a and suppresses EMT in hepatocellular carcinoma

et al. 2016

View full text Add to dashboard Cite

Despite advances in the roles of long non-coding RNA (lncRNA) tumor suppressor candidate 7 (TUSC7) in cancer biology, which has been identified as a tumor suppressor by regulating cell proliferation, apoptosis, migration, invasion, cell cycle, and tumor growth, the function of TUSC7 in hepatocellular carcinoma (HCC) remains unknown. In this study, we observed that the expression of TUSC7 was immensely decreased in HCC. Clinically, the lower expression of TUSC7 predicted poorer survival and may be an independent risk factor for HCC patients. Moreover, TUSC7 inhibited cell metastasis, invasion, and epithelial-to-mesenchymal transformation (EMT) through competitively binding miR-10a. Furthermore, we found that TUSC7 could decrease the expression of Eph tyrosine kinase receptor A4 (EphA4), a downstream target of miR-10a as well as an EMT suppressor, through TUSC7-miR-10a-EphA4 axis. Taken together, we demonstrate that TUSC7 suppresses EMT through the TUSC7-miR-10a-EphA4 axis, which may be a potential target for therapeutic intervention in HCC.

show abstract

“…VIM methylation has been found to be more frequent in bladder urothelial carcinoma and UTUC, but rare in normal tissue, and may therefore be useful as a novel diagnosis and detection method in urothelial cancer. Downregulation of VIM has also been associated with increased tumor invasion, progression, epithelial to mesenchymal transition (EMT) and poor prognosis in various types of tumor (30)(31)(32)(33)(34). Monteiro-Reis et al (31) suggested that during early upper urinary tract carcinogenesis, the VIM promoter is progressively methylated and the gene is kept silenced, as in normal urothelium; by contrast, in a subset of UTUCs, methylation is decreased, allowing for aberrant vimentin expression, due to stimuli leading to EMT.…”

Section: Discussionmentioning

confidence: 99%

Predictive value of gene methylation for second recurrence following surgical treatment of first bladder recurrence of a primary upper‑tract urothelial carcinoma

et al. 2018

View full text Add to dashboard Cite

Abstract. The clinical relevance of aberrant DNA promoter methylation is being increasingly recognized in urothelial carcinoma. The present study was conducted to explore the methylation status of patients with upper-tract urothelial carcinoma (UTUC) who experienced bladder recurrence, and to evaluate the predictive value of gene methylation for second bladder recurrence and tumor progression. A total of 85 patients with primary UTUC, who experienced bladder recurrence after radical nephroureterectomy, were enrolled between January 2001 and December 2013. Using methylation-sensitive polymerase chain reaction, the promoter methylation statuses of 10 genes were analyzed in the bladder tumor specimens. Among the patient group, 32 patients experienced second bladder recurrence, and bladder progression was detected in 16. With the exception of BRCA1, the methylation rate of the majority of genes tended to gradually increase to varying extents with the number of recurrences; a smaller proportion of primary tumors exhibited gene methylation when compared with the first recurrent tumors and second recurrent tumors. Univariate and multivariate Cox regression analyses revealed that unmethylated GDF15 [hazard ratio (HR)=0.36; 95% confidence interval (CI), 0.14-0.92] and methylated VIM (HR=2.91; 95% CI, 1.11-7.61) in the first recurrent bladder tumor, as well as male gender (HR=2.28; 95% CI, 1.06-4.87), first recurrence interval <8 months (HR=2.34; 95% CI, 1.15-4.78) and primary UTUC tumor size ≥5 cm (HR=3.48; 95% CI, 1.43-8.45) were independent risk factors for a second bladder recurrence after surgery for the first bladder recurrence; the Harrell's concordance index (c-index) for the related nomogram was 0.71 (95% CI: 0.61-0.81). Furthermore, methylated CDH1 (HR=2.91; 95% CI, 1.08-7.77) and VIM (HR=4.91; 95% CI, 1.11-21.7) in the first recurrent bladder tumor, male gender (HR=3.6; 95% CI, 1.1-11.73), and primary tumor stage T2-T4 (HR=4.57; 95% CI, 1.22-17.13), multifocality (HR=3.64; 95% CI, 1.19-11.16) and size ≥5 cm (HR=3.1; 95% CI, 1.91-10.54) for the primary UTUC were considered to be predictors of tumor progression; the c-index for the nomogram was 0.88 (95% CI, 0.69-0.92). The present findings demonstrated that promoter methylation of cancer-related genes was frequently observed in patients with urothelial carcinoma, and that the gene methylation rate of certain genes tended to gradually increase with the number of bladder recurrences. This may be used as a predictive factor for a second bladder recurrence and tumor progression after the surgical treatment of the first bladder recurrence.

show abstract

Hypoxia promotes the invasion and metastasis of laryngeal cancer cells via EMT

Cited by 57 publications

References 47 publications

The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis

The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis

Long non-coding RNA TUSC7 acts a molecular sponge for miR-10a and suppresses EMT in hepatocellular carcinoma

Predictive value of gene methylation for second recurrence following surgical treatment of first bladder recurrence of a primary upper‑tract urothelial carcinoma

Contact Info

Product

Resources

About